Skip directly to content

Ibrance®愛搏新®

Ibrance®愛搏新®是⼀種針對激素受體陽性(HR+),第⼆型⼈類上⽪因⼦受體陰性(HER2-)1的乳房細胞的⼀線⼝服標靶藥物,適合關注相關頑症⼈⼠。在本港已被關愛基⾦納入為針對⼀種病症的受資助藥物,協助有需要⼈⼠踏上治療成功之路2

參考資料:

  1. Ibrance® (Palbociclib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (January 2018)
  2. Items Supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#.

 

[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: